No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABT Abbott Laboratories
- 103.200
- 0.0000.00%
Close Jul 2 16:00 ET
- 103.000
- -0.200-0.19%
Post 19:28 ET
179.53BMarket Cap32.15P/E (TTM)
103.390High102.700Low3.65MVolume102.700Open103.200Pre Close376.39MTurnover0.21%Turnover Ratio31.66P/E (Static)1.74BShares121.03952wk High4.63P/B178.39BFloat Cap88.80152wk Low2.08Dividend TTM1.73BShs Float136.153Historical High2.02%Div YieldTTM0.67%Amplitude6.525Historical Low103.105Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
7 Analysts Have This To Say About Abbott Laboratories
Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 7 analysts.The following table provides a quick overview of their recent ratings
Abbott Laboratories Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 16.35% Evercore ISI Group $125 → $120 Maintains Outperform 06/04/2024 21.19% RBC Capital $125 →
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $120
Evercore analyst Vijay Kumar maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $120.According to TipRanks data, the analyst has a success rate of 47.4% and a
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating
Abbott Laboratories (ABT) has an average rating of outperform and price targets ranging from $104 to $143, according to analysts polled by Capital IQ.
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $140
Barclays analyst Matt Miksic maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $140.According to TipRanks data, the analyst has a success rate of 59.5% and a
Comments
Morning Movers
Gapping up
$United Airlines(UAL.US$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories(ABT.US$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
Gapping up
$United Airlines(UAL.US$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories(ABT.US$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
30
$Abbott Laboratories(ABT.US$
Introduction
On April 17th, before the US stock market opened, Abbott (NYSE: ABT) will hold a conference call to announce its financial results for the first quarter of 2024. As a global leader in healthcare, Abbott's performance has been steadily improving in recent years, especially benefiting from the COVID-19 pandemic. According to Bloomberg data, the follow...
Introduction
On April 17th, before the US stock market opened, Abbott (NYSE: ABT) will hold a conference call to announce its financial results for the first quarter of 2024. As a global leader in healthcare, Abbott's performance has been steadily improving in recent years, especially benefiting from the COVID-19 pandemic. According to Bloomberg data, the follow...
1
$Abbott Laboratories(ABT.US$ Hmmm. As usual, red again
Insiders selling shares with no recorded purchases over the last year could worry investors. Despite high insider ownership, recent selling activity suggests insiders don't see shares as a bargain.
The 4- and 5-star rated Dividend Aristocrats for 2024 include Abbott Laboratories, AbbVie Inc., Air Products & Chemicals, and others such as Coca-Cola Co., McDonald's Corp., Walmart Inc., and West Pharmaceuticals.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg